Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 609

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 1A
Chunk 609
---
20243,851,037 $49.62 5.02$6,574 Vested and expected to vest at December 31, 20245,834,256 $43.48 6.21$11,911 The weighted-average grant date fair value of options granted was $18.92, $14.32 and $15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $3.3 million, $2.9 million and $0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively.At December 31, 2024, the total unrecognized compensation expense related to unvested stock option awards was $29.1 million, which we expect to recognize over a weighted-average period of approximately 2.37 years.Restricted stock unitsUpon vesting, each RSU entitles the holder to receive a specified number of shares of our common stock. The following table presents RSU activity for the year ended December 31, 2024:Number ofStock UnitsWeighted-AverageGrant DateFair ValueUnvested shares at December 31, 20231,346,701 $29.67 Granted1,144,164 32.33 Vested(594,511)32.70 Forfeited(77,791)30.86 Unvested shares at December 31, 20241,818,563 $30.31 As of December 31, 2024, there was approximately $33.6 million of total unrecognized compensation expense related to RSUs, which we expect to be recognized over a weighted-average period of 1.87 years.Performance-based stock unitsAt the achievement of the performance-based and service-based vesting criteria, each PSU entitles the holder to receive a specified number of shares of our common stock. The following table presents PSU activity for the year ended December 31, 2024:Number ofStock UnitsWeighted-AverageGrant DateFair ValueUnvested shares at December 31, 2023362,133 $30.66 Granted183,000 32.27 Vested(170,550)35.04 Unvested shares at December 31, 2024374,583 $29.45 Stock-based compensation expense associated